Citi raised the firm’s price target on Olema Oncology (OLMA) to $21 from $20 and keeps a Buy rating on the shares. The firm also added a “90-day upside catalyst watch” on the shares ahead of the Phase 1b/2 mature data evaluating palazestrant plus ribo in ER+/HER2- advanced/metastatic breast cancer. Citi believes presenting the data at an important medical meeting will bring visibility and further share upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals Advances Breast Cancer Therapies
- Olema Pharmaceuticals: Promising Advancements in ER+ Breast Cancer Treatment and Strategic Positioning Justify Buy Rating
- Olema Pharmaceuticals Reports Q2 2025 Financial Results
- Olema Oncology reports Q2 EPS (51c), consensus (44c)
- OLMA Earnings Report this Week: Is It a Buy, Ahead of Earnings?